-
Product Insights
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Report Overview A total of 161 cSCC clinical trials were conducted as of February 2024. The cSCC clinical trial report provides a comprehensive understanding of the Cutaneous Squamous Cell Carcinoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       ...
-
Product Insights
Adenoid Cystic Carcinoma (ACC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenoid Cystic Carcinoma (ACC) - Drugs In Development, 2023’, provides an overview of the Adenoid Cystic Carcinoma (ACC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenoid Cystic Carcinoma (ACC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Ductal Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ductal Carcinoma - Drugs In Development, 2023’, provides an overview of the Ductal Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ductal Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Mammary Ductal Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Mammary Ductal Carcinoma - Drugs In Development, 2023’, provides an overview of the Mammary Ductal Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mammary Ductal Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) - Drugs In Development, 2023’, provides an overview of the NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The...
-
Product Insights
Ductal Carcinoma In Situ – Drugs In Development, 2023
Global Markets Direct’s, ‘Ductal Carcinoma In Situ - Drugs In Development, 2023’, provides an overview of the Ductal Carcinoma In Situ pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ductal Carcinoma In Situ, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Clear Cell Squamous Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Clear Cell Squamous Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Clear Cell Squamous Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Clear Cell Squamous Cell Carcinoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and...
-
Product Insights
Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.